LCN2 and neoplasm: In mice bearing PDX line #5, treatment with the LCN2-neutralizing antibody alone had little effect on tumor growth, whereas the combination treatment achieved a greater anti-tumor effect than sorafenib treatment alone (Fig. 6k, l).